Drug Profile
Research programme: toll-like receptor inhibitors - Dynavax Technologies
Alternative Names: IRS-954Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Developer Dynavax Technologies; GSK
- Class Oligonucleotides
- Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 9 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
- 08 Mar 2016 Dynavax Technologies has patent protection for its TLR agonists and antagonists in USA (Dynavax Technology, Form 10-K, March 2016)
- 28 Nov 2014 Dynavax Technologies regains full rights to all TLR 7/9 inhibitors for all indications